RELIGARE ENTERPRISES LTD. Q1 FY27 Results

Religare Enterprises' consolidated Q1 FY27 (quarter ended June 30, 2026) results show a swing to a net loss of ₹46.98 Cr, against a profit of ₹95.65 Cr in Q4 FY26 and ₹8.17 Cr in Q1 FY26 — consolidated is the primary basis since the insurance subsidiary dominates group revenue. Consolidated revenue from operations rose 26.4% YoY to ₹2,353.40 Cr, driven mainly by insurance premium income, but fell 4.6% QoQ from ₹2,467.42 Cr. Net margin turned negative at -1.99%, reversing from +3.87% in Q4 FY26 and +0.44% in Q1 FY26. No street consensus estimate could be located for this print, so vsStreet is unknown.

The loss is concentrated in the insurance segment (Care Health Insurance), whose segment result swung to a loss of ₹87.27 Cr from a profit of ₹41.26 Cr in Q4 FY26 and a smaller loss of ₹8.30 Cr in Q1 FY26. Two lines drove this: other expenses (largely insurance claims and policy benefits) rose 18.6% QoQ to ₹1,709.97 Cr even as insurance premium income (net) fell to ₹1,978.27 Cr from ₹2,132.37 Cr in Q4 FY26; and the company booked a net loss on fair value changes of ₹71.65 Cr this quarter versus nil in the prior quarter, likely reflecting mark-to-market movement on the insurance investment portfolio. None of these items are labelled exceptional in the filing, so no adjusted-PAT figure is warranted — this reads as an operating and investment-portfolio swing rather than a one-off.

The stock went into the print at ₹240.05, down 8.5% over the past month of trading.

Against management's Q4 FY26 guidance — 18-24% GWP growth and a combined ratio near 100% within two years for Care Health Insurance, plus execution of the REL-RFL demerger as the overarching strategic priority — this quarter reads as a miss: the insurance segment posted a loss rather than progress toward the combined-ratio target, and the RBI rejected the REL-RFL demerger scheme via a letter dated August 6, 2026 (Note 9), a setback to the stated strategy of creating two focused listed entities. No press release or management commentary was available to extract for this filing, so there is no management framing to reconcile against the numbers. On a standalone (parent-only) basis, the loss widened YoY to ₹9.62 Cr from ₹6.15 Cr, though it narrowed QoQ from ₹12.36 Cr — broadly consistent with the group figure, which is dominated by the insurance subsidiary. Other Q1 developments include CHIL's allotment of ₹200 Cr subordinated debt, the company's ₹119.69 Cr subscription to CHIL's rights issue, and allotment of 83.43 lakh shares (₹147.05 Cr received) on warrant conversion; SEBI separately disposed a show-cause notice against the company without directions on August 3, 2026.

Care delivered strong 37% GWP growth and ₹163 Cr PBT, validating insurance strategy. However, consolidated net loss of ₹47 Cr (vs +₹5.73 Cr YoY) reflects financial services drag: housing finance missed 12-18 month profitability target (still -₹5 Cr), NBFC rebuilding with ₹600 Cr idle cash awaiting unproven Q2-Q3 launch, broking flat QoQ despite profitability gains. Demerger blocked by RBI with no clarified alternative path or timeline. Execution risk remains high.

Analysts pressed hard on combined ratio 102.6% vs peers (Q1: Sarvesh), insurance service result math discrepancy (Q2: Mukul), housing AUM stagnation (Q8: Amit), NBFC capital efficiency (Q4: Meet), and demerger reasons (Q0, Q9: Naresh, Meet). Management defended via corporate wellness cost structure, blamed legacy 7-8 year embargo, and deflected on demerger specifics ('RBI gave no reasoning, engaging with regulators'). Notable evasion on full-year guidance (Q2: 'won't comment'), specific growth drivers (Q2: fresh vs. porting split), and binding timelines (Q4, Q8: 'next 3-4 months'). Defensive tone held on capital commitments and warrant timeline (Q10: March 2027).

Score 6/10. Selective transparency. Clear and detailed on Care performance (growth, capital, profitability). Defensive on financial services drag—'rebuilding' framing used to justify losses. Demerger questions deflected ('RBI gave no reasoning, we are engaging'). Insurance combined ratio explained via technical accounting (non-attributable costs), adds opacity. Q&A showed evasion on guidance ('cannot comment on full year'), specifics on growth drivers (fresh vs. porting breakdown), and concrete timelines. Mixed track record evident. Care beat 18-24% GWP guidance at 37% delivery and raised capital on schedule (positive). Housing finance and NBFC missed prior timelines; profitability window for housing closed without target hit. Broking rebounded profitably but revenue flat QoQ—'temporary blip' narrative under pressure. Demerger blocked by RBI—major miss on prior value-unlock strategy. New leadership appointments positive, but early stage.

Religare's Q1 FY27 result will revolve around health insurance premium growth and profitability. The core expectation: Care Health Insurance (CHIL) continues to drive consolidated revenue, with the brokerage and housing finance arms providing stable contributions. Q1 is typically softer seasonally (summer quarter), but growth trajectory from the prior year should be visible. Watch for net premium earned (the insurance revenue that flows through), claim ratios (indicating underwriting health), and consolidated PAT — the latter is sensitive to investment gains and CHIL's profitability.

A strong quarter would show CHIL premiums growing >15% YoY, claims ratio stable or improving, and the group delivering consolidated PAT in line with guidance. A weak quarter would reveal premium growth cooling to single digits, deteriorating claims experience (indicating underwriting losses), or management commentary suggesting the RBI setback has material impact on medium-term strategy. Watch the tone on capital allocation: the recent fundraise signals confidence, but will management confirm deployment plans for growth?

Religare has not publicly disclosed forward guidance for FY27, but the FY26 result (₹8,493.84 Cr consolidated revenue, ₹73.16 Cr PAT) sets the baseline. For Q1 FY27 to be on track, the group should show sequential stability to modest uptick in CHIL premiums. Ownership data shows FII up 1.79pp to 9.64% and DII up 0.81pp to 9.33% in Q1 FY27 vs Q4 FY26, suggesting some institution confidence, though the stock trades 17% below its ATH (₹280), indicating lingering caution on execution and the Scheme rejection.

1. CHIL Premium Growth & Claims Ratio: Is health insurance growing at the 15%+ pace needed to justify the capital raises? Are claims ratios stable or trending worse? This will drive the entire consolidated narrative. A claims ratio >60% (bad) would raise profitability concerns; 2. Management's Plan Post-Scheme Rejection: What is the alternate strategy for REL? Is the capital from promoter warrant conversions now earmarked for organic growth (CHIL) or other priorities? Clarity here will restore investor confidence. 3. Guidance & Capital Allocation Priorities: Will REL reiterate or revise FY27 guidance? When will the warrant dilution be reflected in EPS targets? Visibility on deployment of fresh capital (₹200 Cr CHIL debt + warrant proceeds) will signal conviction.